UNSPSC 51151646: Methylatropine

This classification denotes a parasympatholytic with the molecular formula C18H26NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80719I460H, chemically known as 8-azoniabicyclo(3.2.1)octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8,8-dimethyl-, endo-(+-)- but generally known as methylatropine, which bears US NIH Compound Identifier 5861. World Health Organization schedules methylatropine in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.

UNSPSC 51151646 Methylatropine is a Commodity code that encompasses pharmaceutical products and related drug-delivery systems procured by state and local health agencies. Recent state and local solicitations under this code show purchasing activity concentrated in naloxone procurement and pharmacy benefit program support rather than methylatropine specifically. State and local issuing bodies acquiring under this code include county health departments and state health and human services commissions. Seminole County, Florida, Seminole County health departments, and the Texas Health and Human Services Commission represent the active buyer base in recent months, with activity spanning direct-purchase procurement of emergency medical supplies and strategic information-gathering around pharmaceutical contracting models.

Seminole County, Florida posted an IFB on June 30, 2026 (IFB60459723LAS) seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building at 520 W. Lake Mary Blvd, Sanford, FL 32771, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026 requesting vendor capabilities and market intelligence regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, focused on establishing direct pharmaceutical contracting relationships outside traditional pharmacy benefit manager and group purchasing organization channels. Geographic activity concentrates in Florida and Texas, with the Florida procurement emphasizing operational supply chain execution and the Texas activity emphasizing upstream pharmaceutical procurement strategy development.